Related Experiment Videos
Allogeneic hematopoietic stem cell transplantation for myelofibrosis
H Joachim Deeg1, Theodore A Gooley, Mary E D Flowers
1Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1-100, PO Box 19024, Seattle, WA 98109-1024, USA. jdeeg@fhcrc.org
Blood
|August 16, 2003
Summary
Allogeneic hematopoietic cell transplantation offers long-term, relapse-free survival for patients with myelofibrosis. Busulfan-based conditioning regimens improve survival outcomes, with results comparable between related and unrelated donors.
Area of Science:
- Hematology
- Oncology
- Transplantation Medicine
Background:
- Idiopathic myelofibrosis (IMF) and advanced myeloproliferative neoplasms pose significant challenges.
- Allogeneic hematopoietic cell transplantation (HCT) is a potential curative option.
Purpose of the Study:
- To evaluate the efficacy and outcomes of allogeneic HCT in patients with IMF, polycythemia vera, or essential thrombocythemia.
- To identify risk factors influencing post-transplantation mortality and survival.
Main Methods:
- Retrospective analysis of 56 patients undergoing allogeneic HCT.
- Comparison of conditioning regimens: busulfan plus cyclophosphamide vs. total body irradiation plus chemotherapy.
- Evaluation of stem cell source (marrow vs. peripheral blood) and donor type (related vs. unrelated).
Main Results:
- High engraftment rates (97%) and complete donor chimerism in most patients.
- A 3-year overall survival estimate of 58%.
- Busulfan-based conditioning (800-900 ng/mL) significantly improved survival (76%).
- Dupriez score, cytogenetic abnormalities, and marrow fibrosis were key mortality risk factors.
Conclusions:
- Allogeneic HCT is a viable strategy for achieving long-term, relapse-free survival in myelofibrosis.
- Optimized busulfan-based conditioning enhances transplant outcomes.
- Unrelated donor transplants demonstrated comparable results to sibling transplants.